I'd be interested to see some updated numbers for CDIs v. NASDAQ Common Stock - how many have been converted/gone offshore? Could be a telling indicator of what's going on...
Re bankable numbers, realistically, in the immediate short term, they can only come from three areas:
1 The first of the Supply Agreements with SA for the Unifill.
2. Agreements with additional pharma - will they be complex agreements as with SA, ie License/Drug Classes/Supply, or will they simply be for a particular drug? So say GSK need 100 million syringes per annum for xyz drug/vaccine, the contract value over five years being $123 million.
And will they include up-front license fees as allowed for in the original IA? Even tho' the revenue split is initially weighted in favour of SA, the FACT of additional agreements, with further validation of the technology (if needed), plus diversifiying revenue streams, would do wonders for the SP....you would think....
3. More supply agreements for the 1ml via Stason, or from other distributors covering Europe and other territories. I know the China/Japan approvals will take time, but as Alan said, the process has already commenced so that is already adding value to the company. Time will tell how much! While the main game is obviously the Unifill, 1ml could be a tidy little earner.
Potentially we could also get one from left-field covering the Select - either another tie-up deal with SA or a first-mover signing with some other shop. Either would be a welcome shot in the arm....
In the meantime it's just another educational day in the market....guess we just have to wait and see....
UNS Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
